Hematocrit, Blood Donation, and TRT: Managing Secondary Erythrocytosis (Research Overview)

Testosterone stimulates erythropoietin (EPO) and red blood cell production. On TRT, hematocrit (Hct) typically rises 3-7% from baseline within the first 3-6 months. Most clinicians act when Hct exceeds 52% (some use 54%) to reduce thrombosis risk, especially in users with hypertension, sleep apnea, smoking, or family history of thrombotic events. The first-line interventions in research and clinical practice: therapeutic phlebotomy or whole-blood donation (each removes ~450 mL of blood, dropping Hct by 2-3 percentage points immediately), and protocol adjustments — split larger weekly doses into 2-3 smaller doses to reduce peaks, switch from cypionate/enanthate to a faster ester or daily microdosing, or step the dose down. Hydration is supportive but does not by itself bring elevated Hct down. This content is for research and educational purposes only and does not constitute medical advice.

Testosterone affects red blood cell mass through several mechanisms. It directly stimulates erythropoietin (EPO) production in the kidneys, suppresses hepcidin (a regulator of iron absorption), and may directly stimulate bone marrow erythroid progenitors. The combined effect: more red cells produced, more iron available, and a higher equilibrium hematocrit. The rise is dose-dependent and ester-dependent — higher peak testosterone produces a stronger EPO signal. Research (Coviello et al, J Clin Endocrinol Metab) shows hematocrit rises by an average of 3-5% on standard TRT doses (100-150 mg/week) and by 5-10% on higher doses (200+ mg/week). The plateau is typically reached within 3-6 months and remains stable thereafter unless dose changes. Elevated hematocrit increases blood viscosity. Once Hct exceeds 52-54%, viscosity rises non-linearly, increasing the risk of venous thromboembolism (DVT, PE) and potentially arterial thrombosis (heart attack, stroke). This is the primary clinical concern. The American Urological Association and Endocrine Society guidelines recommend monitoring Hct on TRT and intervening above 52% (Endocrine Society) or 54% (AUA).

Reference ranges: - Normal Hct (men): 40-52% (varies by lab) - Mildly elevated: 52-54% - Significantly elevated: >54% (most guidelines call for intervention) - Polycythemia: >55% Most TRT protocols include Hct monitoring at baseline, 3 months, 6 months, and then every 6-12 months. Some research-oriented users monitor more frequently (every 3 months) during dose changes. When Hct rises above 52% on TRT: 1. **First step**: re-test in 1-2 weeks to confirm (lab variability is real) 2. **If confirmed**: assess hydration status (dehydration alone can elevate Hct) 3. **If still >52%**: consider therapeutic phlebotomy or blood donation 4. **If >54%**: more urgent intervention, dose review, possible TRT pause Users with comorbidities (sleep apnea, smoking, obesity, prior thrombosis) should be more aggressive — many clinicians act at Hct of 50% in this population. Some practitioners prefer to monitor hemoglobin (Hgb) instead of or in addition to Hct. Hgb >18 g/dL (men) is the analogous threshold.

Both procedures remove ~450 mL of whole blood, which immediately drops Hct by 2-3 percentage points and over the next several days drops it by an additional 1-2 points as iron stores deplete and erythropoiesis slows. **Whole blood donation** through the American Red Cross or community blood banks: free, helps the blood supply, but has eligibility requirements. Some donation centers refuse TRT users because of testosterone-related concerns (most don't, but check). Eligibility for blood donation requires Hgb in normal range and weight >110 lbs, plus various health screening. Frequency: every 56 days max for whole blood donation. **Therapeutic phlebotomy** at a hospital or specialty clinic: requires a physician's prescription, typically billed to insurance under polycythemia diagnosis (ICD-10 D75.1 for secondary polycythemia). Cost varies widely; insurance often covers when ordered for medical reasons. Frequency: as needed based on Hct. Research protocols (e.g., Curr Opin Endocrinol Diabetes Obes 2022) suggest 1-2 phlebotomies per year is typical for users on standard TRT doses; users on higher doses (>200 mg/week) may need 3-4 per year. Some users find that donating blood every 8 weeks consistently keeps Hct in range without needing phlebotomy. Others find that one or two donations per year is sufficient. Individual response varies based on baseline Hct, dose, and erythropoietic sensitivity.

Beyond removing blood, several protocol changes reduce hematocrit elevation at the source: **Increase injection frequency.** A 200 mg/week dose given as 200 mg once weekly produces higher peaks than 100 mg twice weekly, which produces higher peaks than 67 mg three times weekly, which produces higher peaks than 28 mg daily. Higher peaks drive more EPO secretion. Daily or every-other-day microdosing typically produces 2-4% lower steady-state Hct than weekly dosing at the same total dose. **Switch from cypionate/enanthate to propionate or daily-administered formulations.** Faster esters produce sharper peaks but those peaks are shorter — net AUC effect on EPO appears similar or slightly less in research. **Reduce total dose.** The most direct intervention. Going from 200 mg/week to 150 mg/week typically drops Hct by 1-3 percentage points over 3-6 months, but also reduces the therapeutic effect of TRT. This is a balancing act with the prescriber. **Topical/transdermal switch.** Transdermal testosterone (gel, cream) tends to produce lower hematocrit elevation than injectable testosterone because peak serum levels are lower (Layton et al, J Clin Endocrinol Metab 2018). Some users with persistent hematocrit issues switch to transdermal as a last resort. **HCG addition.** Some research suggests HCG addition does not significantly increase hematocrit beyond what testosterone alone does, but data are mixed. HCG may help maintain testicular function without further EPO stimulation. **Aspirin.** Low-dose aspirin (81 mg/day) is sometimes used to reduce thrombotic risk in users with elevated Hct, but this is off-label and bleeding risk must be weighed. Discuss with prescriber.

Several factors interact with TRT to influence hematocrit: **Sleep apnea.** Untreated obstructive sleep apnea elevates EPO independently of TRT. Users on TRT with undiagnosed OSA can see Hct elevations >55% even on modest doses. Symptoms: snoring, witnessed apneas, daytime fatigue, morning headaches. A sleep study and CPAP therapy can dramatically reduce hematocrit issues. **Smoking.** Carbon monoxide from smoking reduces oxygen-carrying capacity, prompting compensatory EPO secretion. Smokers on TRT have substantially higher hematocrit than non-smoking matched controls. **Altitude.** High-altitude residents have higher baseline Hct due to chronic hypoxia. TRT users at altitude may see Hct elevations sooner than sea-level users. **Dehydration.** Acute dehydration can falsely elevate Hct (concentration effect). Drink water before any blood draw — chronic dehydration is uncommon in healthy users but can mask or amplify true Hct elevations. **Polycythemia vera (PV).** A myeloproliferative neoplasm with JAK2 mutation that elevates Hct independently of any external stimulus. Distinguishing primary PV from TRT-induced secondary erythrocytosis matters because PV requires hematology referral and different treatment. EPO levels (low in PV, normal/high in secondary erythrocytosis) and JAK2 testing are diagnostic.

Dosed logs lab values over time alongside the protocol that produced them. Users can see Hct trends across dose changes, frequency changes, ester changes, and phlebotomy events on a single visual timeline. The app also tracks reconstitution and dose history, so when a user discusses Hct concerns with their prescriber, the timeline of dose-response is in one place. For users managing chronic hematocrit elevation, Dosed logs phlebotomy and donation events to support proper interval planning. This content is for research and educational purposes only and does not constitute medical advice.

**Mistake 1: Donating blood right before lab draw.** This produces an artificially low Hct reading and masks the true picture. Time labs at least 4-6 weeks after a donation to capture steady-state Hct. **Mistake 2: Ignoring Hct trends because the absolute number is 'still in range.'** Hct rising from 42% to 51% is significant, even though 51% is technically normal. Catching the trend early allows for protocol adjustments before reaching threshold. **Mistake 3: Assuming hydration alone will fix elevated Hct.** Acute dehydration produces 1-2% transient elevation. Chronic Hct elevation on TRT is real EPO-driven erythrocytosis and requires real intervention. **Mistake 4: Overcorrecting with too-frequent donations.** Donating every 8 weeks aggressively can cause iron deficiency anemia (low ferritin, fatigue, hair loss). Track ferritin annually if donating regularly; supplement iron if ferritin <50 ng/mL. **Mistake 5: Skipping investigation for sleep apnea or other comorbidities.** Persistent Hct elevation despite reasonable protocol adjustments may indicate undiagnosed OSA, smoking-related polycythemia, or polycythemia vera. Workup the underlying cause.